# How to Validate a Digital Biomarker When There’s No Gold Standard: Leveraging Convergent Validity and Clinical Anchors

The promise of digital biomarkers—from wrist-worn accelerometers to voice-based depression monitors—depends entirely on one uncomfortable question: how do you prove a sensor-derived signal is measuring what it claims to measure when no perfect reference exists? In many therapeutic areas, the gold standard either doesn’t exist, is too invasive, or is impractical for continuous monitoring. The answer isn’t to force a comparison that doesn’t fit. Instead, a growing consensus is emerging around a pragmatic hybrid approach: using convergent validity to build evidence of construct alignment and clinical anchors to demonstrate real-world meaning. For teams developing digital measures in 2026, this isn’t just a statistical exercise—it’s a strategic pathway to regulatory alignment, clinical adoption, and payer coverage.

Why Classic Validation Falls Short for Digital Measures

Traditional validation protocols assume a clear criterion. A new blood glucose monitor is validated against a lab reference; an ECG algorithm is tested against a cardiologist’s interpretation. But digital biomarkers often measure latent constructs—fatigue, cognitive load, gait variability, emotional state—that don’t have a single observable truth. Worse, the very act of measurement can alter the phenomenon, and sensor-derived data are frequently confounded by context, device placement, and user behavior.

The standard psychometric toolkit, built for questionnaires and lab tests, doesn’t translate perfectly. Reliability indices like Cronbach’s alpha assume item-level interchangeability, and criterion validity assumes an anchor that can be measured with far less error than the test itself. When neither holds, researchers must think differently. The solution is to triangulate evidence from multiple sources—convergent validity tells you whether your biomarker aligns with other measures of the same construct, while clinical anchors provide interpretable thresholds that bridge the gap between raw signals and patient-important outcomes.

Reframing Validation: From “Trueness” to Clinical Utility

A useful shift for digital biomarker validation is to stop asking “is it true?” and instead ask “is it useful?” This pragmatic approach recognizes that no measurement is perfect, but a digital biomarker can still provide value if it consistently tracks a clinically meaningful construct and responds to interventions or events in expected ways. In this view, validation is an ongoing process of accumulating evidence, not a single binary pass/fail test.

For example, a smartwatch-based gait speed estimate may not precisely match a motion-capture laboratory system, but if it predicts fall risk in older adults over the next six months and correlates with the Timed Up and Go test, it earns its place as a clinical monitoring tool. The key is to align the validation strategy with the intended use. Digital biomarkers used for safety monitoring require different evidence than those used for diagnostic classification or treatment response. Defining the intended use upfront clarifies which clinical anchors are relevant and what level of agreement is sufficient.

Step 1: Map the Construct and Define the Clinical Anchor

Before any data is collected, your team must articulate exactly what the digital biomarker is supposed to represent. This is where construct mapping becomes essential. Break the target construct into observable component behaviors and decide which of those are measurable from your sensor channel. Then, identify at least one clinical anchor—a measurement that clinicians already trust, even if it isn’t perfect. The anchor should be meaningful to clinical decisions and ideally independent of the sensor itself.

Clinical anchors can take many forms. A patient-reported outcome (PRO) like the Patient Health Questionnaire-9 (PHQ-9) can serve as a weekly reference for a voice-acoustic depression biomarker. A clinician-administered scale such as the Unified Parkinson’s Disease Rating Scale (UPDRS) may anchor a wearable tremor measure. More objective anchors, like a six-minute walk test distance or a cognitive battery score, are also valuable. The anchor doesn’t need to be a gold standard—it needs to be clinically credible and conceptually aligned with the digital measure. Document the relationship between the digital signal and the anchor in a prespecified analysis plan, and avoid cherry-picking outcomes after seeing the data.

Step 2: Design a Convergent Validity Protocol

Convergent validity is straightforward in theory: your digital biomarker should correlate with another measure that is believed to capture the same underlying construct. However, in practice, you need a thoughtful design to avoid inflated or misleading correlations. Consider the timing of measurements. If your digital biomarker captures daily fluctuations in energy and your anchor is a one-time clinic visit, you need to decide whether you expect a cross-sectional correlation or a longitudinal association. For many digital measures, the strongest evidence comes from within-person change scores: when a patient reports worsening fatigue, does the sensor metric also shift in the expected direction?

A robust convergent validity protocol for a novel digital biomarker might include multiple comparison measures, each probing a slightly different facet of the construct. For example, a smartphone-based cognitive digital biomarker could be compared with a standard neuropsychological test for processing speed, a working memory task, and a real-world performance measure like driving simulator errors. Agreement across these diverse but related measures strengthens the argument that you are measuring a broad cognitive construct rather than a single artifact of one particular test. It also reduces the likelihood that your biomarker is only measuring reaction time or smartphone familiarity.

Step 3: Quantify Agreement with the Right Metrics

Once the data are in, selecting the right statistical metrics is critical. Pearson or Spearman correlation coefficients are a common starting point, but they only capture linear association, not agreement. Two measures can be strongly correlated yet systematically differ by a meaningful amount. For continuous digital biomarkers, Bland-Altman plots and intraclass correlation coefficients (ICCs) provide more useful information about bias and consistency. For categorical or ordinal anchors, weighted kappa statistics should be used.

Still, avoid the trap of applying overly strict thresholds designed for lab tests. Digital biomarkers are often noisier and more context-sensitive than a fasting blood draw. A clinically acceptable level of agreement should be defined a priori based on the intended use. If the biomarker is meant to detect large changes in functional status, a modest ICC of 0.6 might be perfectly adequate. If it’s meant to titrate a medication dose, you’ll need much higher precision. Think in terms of clinical utility: what is the smallest change that matters for patient management? This approach shifts the conversation from statistical perfection to decision impact.

Step 4: Ground Truth via Clinical Outcomes and Proxies

Even when no gold standard exists, clinical outcomes can provide a powerful form of external validation. The logic is simple: if a digital biomarker is meaningful, it should predict or correlate with important endpoints like hospitalization, disease progression, or survival. This kind of predictive validation is especially valuable in chronic diseases where outcomes take months or years to develop. For example, a sensor-based measure of daily activity in people with heart failure can be validated by its ability to predict 30-day hospital readmission. The readmission is the clinical anchor—not because it perfectly measures frailty or functional status, but because it represents a downstream consequence that matters to patients and healthcare systems.

Clinical proxies can also serve as anchors when true outcomes are rare or delayed. In neuropsychiatric research, a digital biomarker measuring sleep fragmentation might be anchored to markers like cortisol awakening response or inflammatory cytokines, which are established intermediate mechanisms. The key is to explain the hypothesized causal chain between the digital signal and the anchor. That logic is what makes the evidence compelling to regulators and clinical reviewers, rather than a purely statistical exercise.

Step 5: Contextualize with Known Groups and Longitudinal Change

Another powerful and practical strategy is known-groups validation. If you are developing a digital biomarker for cognitive impairment, you should see clear differences between healthy older adults, people with mild cognitive impairment, and those with Alzheimer’s disease. Similarly, a mood-sensing biomarker should show different distributions in depression versus euthymic states. Known-group comparisons are easy to explain and provide immediate face validity, but they are not sufficient on their own. They need to be combined with longitudinal evidence that the biomarker tracks change over time within individuals.

Longitudinal change is the most clinically relevant type of validity for monitoring applications. Does the digital signal improve when a patient begins an effective therapy? Does it worsen during a documented relapse? By embedding repeated digital measurements and repeated anchor assessments into an observational study, you can model whether the two move together over time. Mixed-effects models that estimate within-person coupling are particularly useful here, as they separate between-person differences from within-person dynamics. This kind of evidence directly supports the biomarker’s use as an endpoint in future clinical trials.

Practical Considerations for Regulators and Payers

Regulatory agencies and health technology assessment bodies increasingly expect a well-documented validation framework rather than an impossible standard of perfection. In the European Union and the United States, digital biomarker qualification programs emphasize fit-for-purpose validation. That means your evidence package must demonstrate that the biomarker works for its claimed context of use. Convergent validity and clinical anchors are exactly the types of evidence that can support this claim. It is also important to publish negative results—for example, showing that a biomarker does not correlate with an unrelated construct—to establish discriminant validity.

Payers are similarly interested in whether the biomarker changes clinical management or improves patient outcomes. A validation strategy that connects sensor data to a clinically meaningful anchor—such as reduced emergency visits or better medication adherence—is more compelling than one that only reports correlation coefficients. So when you design your validation study, think beyond the research team. Consider the questions a skeptical clinician or reimbursement analyst might ask. Your goal is to build an evidence narrative where the digital biomarker earns its place not by being perfect, but by being useful and interpretable in everyday care.

Conclusion

Validating a digital biomarker without a gold standard is not a hopeless endeavor—it simply requires shifting from a search for absolute truth to a pluralistic evidence strategy. By integrating convergent validity across multiple reference measures, anchoring the digital signal to clinical outcomes and established clinical tools, and demonstrating utility in known groups and longitudinal settings, you can build a compelling case that a novel measure is fit for purpose. The future of digital medicine isn’t about finding perfect reference standards; it’s about assembling enough weave of evidence to trust a signal in the moments when it matters most.